Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma

References

• Catovsky D, Ikoku NB, Pitney WR, et al. Thromboembolic complications in myelomatosis. BMJ 1970;3:438–439.
   PubMed Web of Science ®Google Scholar
• Kristinsson SY. Thrombosis in multiple myeloma. Am Soc Hematol Educ Program 2010:437–444.
   Google Scholar
• Libourel EJ, Sonneveld P, van der Holt B, et al. High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. Blood 2010;116:22–26.
   PubMed Web of Science ®Google Scholar
• Auwerda JJA, Sonneveld P, de Maat MPM, et al. Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica 2007;92:279–280.
   PubMed Web of Science ®Google Scholar
• Elice F, Fink L, Tricot G, et al. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 2006;134:399–405.
   PubMed Web of Science ®Google Scholar
• Jiménez-Zepeda VH, Domínguez-Martínez VJ. Acquired activated protein C resistance and thrombosis in multiple myeloma patients. Thromb J 2006;4:11.
   PubMedGoogle Scholar
• Zangari M, Elice F, Fink L, Tricot G. Thrombosis in multiple myeloma. Expert Rev Anticancer Ther 2007;7:307–315.
   PubMed Web of Science ®Google Scholar
• Zamagni E, Brioli A, Tacchetti P, et al. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. Semin Thromb Hemost 2011;37:209–219.
   PubMed Web of Science ®Google Scholar
• Van Marion AMW, Auwerda JJA, Minnema MC, et al. Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis. Thromb Haemost 2005;94:1341–1343.
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Pfeiffer RM, Björkholm M, et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood 2010;115:4991–4998.
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Fears TR, Gridley G, et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 2008;112:3582–3586.
   PubMed Web of Science ®Google Scholar
• Snowden JA, Ahmedzai SH, Ashcroft J, et al. and Haemato-oncology Task Force of British Committee for Standards in Haematology and UK Myeloma Forum. Guidelines for supportive care in multiple myeloma 2011. Br J Haematol 2011;154:76–103.
   PubMed Web of Science ®Google Scholar
• Baglin T. Using the laboratory to predict recurrent venous thrombosis. Int J Lab Hematol 2011;33:333–342.
   PubMed Web of Science ®Google Scholar
• Toukh M, Siemens DR, Black A, et al. Thromboelastography identifies hypercoagulablilty and predicts thromboembolic complications in patients with prostate cancer. Thromb Res 2014;133: 88–95.
   PubMed Web of Science ®Google Scholar
• Ay C, Dunkler D, Simanek R, et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Am Soc Clin Oncol 2011;29:2099–2103.
   PubMed Web of Science ®Google Scholar
• Treliński J, Misiewicz M, Robak M, et al. Assessment of rotation thromboelastometry (ROTEM) parameters in patients with multiple myeloma at diagnosis. Thromb Res 2014;133:667–670.
   PubMed Web of Science ®Google Scholar
• Lipets E, Vlasova O, Urnova E, et al. Circulating contact-pathway-activating microparticles together with factors IXa and XIa induce spontaneous clotting in plasma of hematology and cardiologic patients. PloS One 2014;9:e87692.
   PubMed Web of Science ®Google Scholar
• Seregina EA, Nikulina OF, Tsvetaeva NV, et al. Laboratory tests for coagulation system monitoring in a patient with β-thalassemia. Int J Hematol 2014;99:588–596.
   PubMed Web of Science ®Google Scholar
• Soshitova NP, Karamzin SS, Balandina AN, et al. Predicting prothrombotic tendencies in sepsis using spatial clot growth dynamics. Blood Coagul Fibrinolysis 2012;23:498–507.
   PubMed Web of Science ®Google Scholar
• Ovanesov MV, Lopatina EG, Saenko EL, et al. Effect of factor VIII on tissue factor-initiated spatial clot growth. Thromb Haemost 2003;89:235–242.
   PubMed Web of Science ®Google Scholar
• Panteleev MA, Ovanesov MV, Kireev DA, et al. Spatial propagation and localization of blood coagulation are regulated by intrinsic and protein C pathways, respectively. Biophys J 2006;90:1489–1500.
   PubMed Web of Science ®Google Scholar
• Tarandovskiy ID, Balandina AN, Kopylov KG, et al. Investigation of the phenotype heterogeneity in severe hemophilia A using thromboelastography, thrombin generation, and thrombodynamics. Thromb Res 2013;131:e274–280.
   PubMed Web of Science ®Google Scholar
• Castoldi E, Rosing J. Thrombin generation tests. Thromb Res 2011;127(Suppl. 3):S21–25.
   PubMed Web of Science ®Google Scholar
• Chitlur M, Warrier I, Rajpurkar M, et al. Thromboelastography in children with coagulation factor deficiencies. Br J Haematol 2008;142:250–256.
   PubMed Web of Science ®Google Scholar
• Robak M, Treliński J, Chojnowski K. Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma. Med Oncol (Lond) 2012;29:3574–3580.
   PubMed Web of Science ®Google Scholar
• Baker BA, Adelman MD, Smith PA, et al. Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays. Arch Intern Med 1997;157:2475–2479.
   PubMed Web of Science ®Google Scholar
• Al Dieri R, Alban S, Béguin S, et al. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. J Thromb Haemost 2004;2:1395–1401.
   PubMed Web of Science ®Google Scholar
• Zmuda K, Neofotistos D, Ts'ao CH. Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation. Am J Clin Pathol 2000;113:725–731.
   PubMed Web of Science ®Google Scholar
• Muedra V, Bonanad S, Gómez M, et al. Relationships between antithrombin activity, anticoagulant efficacy of heparin therapy and perioperative variables in patients undergoing cardiac surgery requiring cardiopulmonary bypass. Perfusion 2011;26:487–495.
   PubMed Web of Science ®Google Scholar
• Fries D. Thrombosis prophylaxis in critically ill patients. Wien Med Wochenschr 1946 2011;161:68–72.
   PubMedGoogle Scholar
• Uprichard J, Manning RA, Laffan MA. Monitoring heparin anticoagulation in the acute phase response. Br J Haematol 2010;149:613–619.
   PubMed Web of Science ®Google Scholar
• Ranucci M, Isgrò G, Cazzaniga A, et al. Predictors for heparin resistance in patients undergoing coronary artery bypass grafting. Perfusion 1999;14:437–442.
   PubMed Web of Science ®Google Scholar
• Urbauer E, Kaufmann H, Nösslinger T, et al. Thromboembolic events during treatment with thalidomide. Blood 2002;99:4247–4248.
   PubMed Web of Science ®Google Scholar
• Lejhancova-Tousovska K, Zapletal O, Vytiskova S, et al. Profile of thrombin generation in children with acute lymphoblastic leukemia treated by Berlin-Frankfurt-Münster (BFM) protocols. Blood Coagul Fibrinolysis 2012;23:144–154.
   PubMed Web of Science ®Google Scholar
• Elting LS, Rubenstein EB, Martin CG, et al. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol 2001;19:1137–1146.
   PubMed Web of Science ®Google Scholar